Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | OGFRL1 | Q5TC84 | 5/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62151 | 0.82 | ADORA3 (0.37) | ADORA3CTSLCTSBCTSSCTSK | |
| SCHEMBL63621 | 0.78 | ROCK2 (0.38) | ADORA3CTSLCTSBCTSSCTSK | |
| SCHEMBL52246 | 0.77 | HPGD (0.37) | ADORA3CTSLCTSBCTSSCTSK | |
| SCHEMBL51466 | 0.76 | OGFRL1 (0.34) | ADORA3OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL13657351 | 0.76 | OGFRL1 (0.37) | OGFRL1OPRM1OPRK1OPRD1KDM4E | |
| SCHEMBL62733 | 0.75 | OGFRL1 (0.35) | OGFRL1OPRM1OPRK1OPRD1HPGD | |
| SCHEMBL52145 | 0.75 | SIGMAR1 (0.37) | ADORA3SIGMAR1OGFRL1OPRM1OPRK1 | |
| SCHEMBL9942884 | 0.74 | P2RX7 (0.34) | HPGDKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL61886 | 0.73 | HPGD (0.38) | ADORA3CTSLCTSBCTSSRORC | |
| SCHEMBL63586 | 0.73 | KMT2A (0.31) | OGFRL1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | ADORA3 1885/4885SIGMAR1 4204/4885CTSL 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.